Skip to content
JWEL

Jowell Global Ltd.

Jowell Global Ltd. Q4 FY2025 earnings call

February 26, 2026 · fiscal period ended 2025-12

EPS · actual vs est

/

Revenue · actual vs est

/
Ask about this call

Summary

Generated 2026-02-26

Management highlights

2025 was a strong year for Jameson Wellness with 12% consolidated revenue growth. Key markets like China saw over 56% revenue growth driven by performance marketing and brand awareness. Utheory had double-digit growth. Canada outpaced the market with 6% revenue growth. Innovation was key across markets. Looking to 2026, expecting strong branded growth with growth plans for various regions.

View in transcript ↓

Segment performance

In the fourth quarter, consolidated revenue increased 13.4% to $277.7 million. Jameson Brands grew 17.1% to $237.4 million, with China revenue up 43.9%, US Utheory up 20.2%, Canada up 5.5%, and international up 39.2%. Strategic partner revenues declined by 4.4%.

View in transcript ↓

Guidance

2026 consolidated revenue expected between $895 million and $935 million. Jameson Brands revenue expected $790-$820 million. China revenue growth 20%-30%, US 14%-19%, Canada 4%-6%, international 10%-15%. Strategic partner revenues to return to growth. Adjusted EBITDA expected $174-$181 million, adjusted diluted earnings per share $2.08-$2.21.

View in transcript ↓

Risks

Mentioned potential acquisition did not meet stringent criteria. Also, risk factors from press release to be referred to for actual results differing from forward-looking statements.

View in transcript ↓

Q&A highlights

Q: Steven McLeod from BMO Capital Markets asked about evolution of performance marketing investments in 2026.

A: Mike said conversion rates increasing, expecting more growth in 2026.

Q: Asked about Canada consumption volumes vs market.

A: Canada outpaced mid single digit category growth.

Q: Justin Keywood from Stifel asked about confidence in 2026 growth.

A: Mentioned marketing, innovation, global category growth.

Q: Asked about flu season impact on immunity.

A: Immunity grew in Dec 2025 but less material now.

Q: Asked about M&A criteria and pipeline.

A: Looking for scaled quality brand, min $100M, focus on US.

Q: Nate Poe from National Bank Capital Markets asked about EBITDA margin and seasonality.

A: China ahead of margin expectations, seasonality consistent.

Q: Ryland Conrad from RBC Capital Market asked about Utheory innovation and China margin trajectory.

A: Utheory innovation more balanced, China margin evolution slow build.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS
Revenue

Transcript

February 26, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.